Emerging developer of rapid immunoassay tests for infectious diseases expands product registration with clinivation’s worldwide Approvals solution.
Natick, MA, November 20, 2007 – clinivation, Inc. announced today that StatSure Diagnostic Systems, Inc. (NASDAQ: SSUR.OB) has selected clinivation’s Approvals solution.”StatSure is leading the way in next-generation rapid immunoassay tests for use in the detection of infectious diseases,” said Joseph Kozikowski, M.D., clinivation’s President and Chief Executive Officer. “We are pleased that StatSure’s senior management has selected clinivation to help position its upcoming regulatory approvals,” he continued.Clinivation’s Approvals Practice delivers regulatory expertise, development strategy, and an outstanding track record.
About StatSure Diagnostic Systems, Inc.
StatSure Diagnostic Systems, Inc., (SDS), a Delaware corporation (the “Company”), is primarily engaged in the development and marketing of oral fluid collection devices for the drugs of abuse market, and rapid immunoassays for use in the detection of infectious diseases. The Company believes that its patented platform for rapid testing of infectious diseases offers significant advantages over the competition, including ease-of-use, lower costs, and significantly reduced risk of infection from collecting and handling specimens. In the oral fluid collection market, the Company’s platform has a patented internal quality control that indicates sufficient volume of the oral fluid (“volume adequacy indicator”).
For additional information, please visit www.statsure.com.
